No gainer or loser data available.

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Imagion Biosystems (ASX:IBX): Making the business case for MagSense® cancer imaging

Transcription of The Stock Network Interview with Imagion Biosystems (ASX:IBX), President Ward Detwiler

Lel Smits: Imagine Biosystems has launched 10 Things to Know About MagSense, a new series setting out the business case for its non-radioactive molecular MRI imaging agent. Part one explains how MRI manufacturers, contrast media companies, and radiopharmaceutical developers each stand to benefit alongside the company’s FDA-cleared US clinical trial in HER2-positive breast cancer. President Ward Deitweiler joins the Stock Network to discuss what MagSense offers MRI manufacturers and contrast media companies and the commercial milestones ahead.

MRI gives doctors detailed pictures, but it can’t always tell whether an abnormality is cancer. How does MagSense change that and why does Imagine expect MRI manufacturers to embrace it?

Ward Detwiler: So in my view, I think the easiest way to think about how MagSense improves MRI is to think about the check engine light in your car. That’s MRI today.

It can tell you when something is wrong, but it can’t tell you exactly what the problem is. So when that light goes off, you still need to bring your car to the shop, get other diagnostics done, spend more time and money before you know what, if anything, is actually wrong and what to do about it. MagSense is like if your car gave you that answer right on the dash.

Because MagSense is molecularly targeted to a specific type of cancer, which in this case HER2-positive breast cancer, if you see the unique image pattern of MagSense, you know the only reason that it’s there is because HER2 cancer cells are present. And that is very important because it could potentially reduce the need for biopsies, which could add cost and time, could lead to unwanted side effects for patients. It could lead to better, more targeted treatment and potentially provide longer-term follow-up information about how the cancer is responding.

And all of that really raises the value in the utilization of MRI and oncology.

Now, why is that important to MR manufacturers? MRI is getting pressure from two sides. At the low end, we’ve got CT and ultrasound with cheaper and faster, albeit not as detailed imaging, which are gaining adoption as healthcare systems see increased economic pressure.

On the higher end, you’ve got PET, which, while being multiples more expensive and hampered by complex workflows and safety concerns, provides that molecular specificity. MagSense offers MRI manufacturers access to a tool that is highly sensitive and specific, but without the cost, workflow constraints and radiation exposure of PET. So I think it will help expand MRI utilization in oncology and ultimately market share for manufacturers.

And I think our ongoing collaboration with Siemens is evidence of that interest already. And we hope to expand our industry collaborations further as we progress with the phase two trial and are able to share more clinical data. And so what are contrast media companies and why are they important in this story? So in the field of MRI, contrast media companies primarily refers to the manufacturers of gadolinium, which is a substance that is injected prior to an MR scan in order to improve the visualization of blood flow and other areas of increased vascular activity.

In layman’s terms, it’s sort of like a highlighter for MRI, except that instead of highlighting just a few key phrases, it highlights the entire page. You can’t tell exactly what is important and what’s just noise. So a bright spot could be due to an active tumor, but it could be a number of other things.

So while it can be sensitive, it is not specific. And because of the physics of gadolinium, you can’t just attach a targeting compound to it like you can with MagSense. Gadolinium has also been in use since the late 80s.

And like a lot of things that were once novel, there’s now a tremendous amount of competition resulting in lower margins and diminishing returns on R&D. On top of that, there are some unresolved safety concerns related to long-term deposition. And addressing that is actually where a lot of R&D is currently directed.

That said, these companies have established sales channels and are universally integrated into radiology workflows. So for the gadolinium traditional contrast media companies, I think MagSense offers a real opportunity for them. It offers them a higher value product with the molecular specificity, de-risked R&D, and a better safety profile, all of which can be sold through their existing sales operations.

So MagSense, it doesn’t replace gadolinium. Rather, it expands the contrast media companies’ portfolios with a highly complementary product. The next part of the series looks at market size, supply chains, and health economics.

What will that show investors about the commercial opportunity, and what milestones are next for MagSense? So I think we’ve already talked about why some of the large strategic partners are going to be interested in MagSense and why this will be appealing to them. But I think there’s also some real market fundamentals that ultimately will make MagSense successful in the clinical market. You hear a lot of times from tech companies saying how they’re going to disrupt an entire industry, and that can sound very flashy and exciting.

But healthcare is not built on disruption. It is built on precision, reliability, repeatability, and ultimately economics. And that applies both in clinical workflow and in supply chain.

To be reliably commercially successful, you want to fit existing supply chains, fit existing workflows, demonstrate strong economics, solve real problems in big markets, and have the opportunity to scale. And MagSense hits on all of those points. First, we fit existing clinical practice.

Radiologists are trained to administer and read contrast-enhanced exams. Beyond that, we don’t require any special handling or complex supply chains like Petmite. It fits existing clinical and operational workflows.

We’ve performed early health economic studies that justify a premium price, and we run an existing MR system, so we avoid new capital expenditures. Finally, we have a platform that can be extended across a number of clinical applications, addressing long-standing diagnostic problems facing millions of patients and their physicians across the globe. I really look forward to expanding on that as we dive into the next chapters of this series.

But from where I sit, the economics and the value proposition of MagSense really make sense and fit the health care market and how these companies grow and are successful. Getting there is still going to require some work, obviously, and all of that starts with our Phase II trial in HER2 breast cancer, which I think will be a big inflection point and a signal to those strategic partners as that data starts to come in. So getting our first sites active and opening the study for enrollment are really the next major milestones for us, and that’s something that our team has really been laser-focused on since we received our IND clearance, and we look forward to sharing that news with the market in the very near future.

Lel Smits: Ward, thank you for joining the Stock Network.

Ward Detwiler: Thanks. Thanks for having me.

Ends